will semaglutide lower blood pressure Does Affect Pressure? Clinical Insights While semaglutide and tirzepatide are

When to seek urgent medical attention : Severe, persistent abdominal pain that does not resolve (if pancreatitis is suspected, stop taking the medication and seek immediate medical assessment) Signs of dehydration from persistent vomiting or diarrhoea (which can lead to acute kidney injury) Allergic reactions (rash, difficulty breathing, swelling of face or throat) Symptoms of hypoglycaemia if taking other glucose-lowering medications (shakiness, confusion, sweating) Regular follow-up with your healthcare team is essential to monitor your response to treatment, adjust doses appropriately, and address any concerns promptly

1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization

The same goes for non-prescription items advised by a physician alongside your medication

Residual confounding cant be ruled out

Changes in HbA1c throughout the study were also not associated with reduced MACE.24 Additionally, the multiple pleiotropic effects of SEMA on metabolic, hepatic and renal function may indirectly contribute to cardiovascular protection.25 The HFpEF programme shows significant symptomatic improvement of heart failure symptoms with preserved ejection fraction (HFpEF) in obese patients treated with SEMA 2.4 mg26 (Fig